Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Captopril, but not nifedipine, improves endothelium-dependent vasodilation in hypertensive patients

Abstract

The present study aimed to investigate the influence of the angiotensin-converting enzyme (ACE)-inhibitor captopril and the Ca-antagonist nifedipine on endothelium-dependent vasodilation (EDV) in the forearm of hypertensive patients. Twenty-three middle-aged untreated hypertensive patients underwent evaluation of EDV and endothelium-independent vasodilation (EIDV) in the forearm, by means of local intra-arterial infusions of methacholine (MCh, evaluating EDV) and sodium-nitroprusside (SNP, evaluating EIDV), before and 1 h after intake of either captopril (25 mg) or nifedipine (10 mg) in a randomised, double-blind fashion. A matched normotensive control group was investigated at baseline conditions only. Five of the hypertensives were also evaluated after 3 months of treatment with captopril 25 mg twice daily in an open pilot study.

First, the vasodilation induced by methacholine (MCh), but not SNP, was significantly attenuated in the hypertensive patients compared to the normotensive controls (P < 0.001 at mch 4 μg/min).

Second, although the two drugs induced a similar decline in blood pressure (BP) 1 h after administration (−11 to 10 mm Hg/−8 to 7 mm Hg), captopril significantly potentiated the vasodilator response to MCh (+32 ± 13%, MCh 4 μg/min, P < 0.01) but not snp, while nifedipine did not significantly alter the response to either mch or snp. the improvement in vasodilator response to mch induced by captopril was closely related to the reduction in bp (r = 0.72, P < 0.01).

Third, in the pilot study, 3 months of captopril treatment induced a significant potentiation of the vasodilator response to MCh (+34 ± 17%, MCh 4 μg/min, P < 0.05) in parallel with a significant bp reduction (−22 ± 24/13 ± 13 mm hg, P < 0.05), while the response to snp was unchanged.

In conclusion, the present study confirmed that essential hypertension is associated with a defect in EDV. Furthermore, an improvement in EDV was seen in hypertensive patients shortly after administration of captopril, but not nifedipine. In addition, a significant beneficial effect on EDV was seen in a small pilot study during long-term treatment with captopril.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

Rights and permissions

Reprints and permissions

About this article

Cite this article

Millgård, J., Hägg, A., Sarabi, M. et al. Captopril, but not nifedipine, improves endothelium-dependent vasodilation in hypertensive patients. J Hum Hypertens 12, 511–516 (1998). https://doi.org/10.1038/sj.jhh.1000665

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.jhh.1000665

Keywords

This article is cited by

Search

Quick links